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| INTRODUCTION
Platelet aggregation is most commonly measured by light transmission aggregometry (LTA), in which the increase in light transmission through a stirred suspension of platelet-rich plasma (PRP) is measured over time as platelets aggregate, and plotted graphically. The technique has changed little since being first described in the early 1960s, 1,2 but the assessment of platelet aggregation to a range of agonists is central to the investigation of platelet function disorders. [3] [4] [5] It is only tested by a few specialized hemostasis laboratories, 6 since the processes of sample preparation, analysis and the subtle interpretation of the curves produced require considerable expertise and familiarity to diagnose platelet function defects.
Recently, however, an automated LTA method has been described that offers potential standardization of measurement, and a less laborious analytical process. Lawrie et al 7 In this multicenter study, we have analyzed residual PRP from 64 patients being investigated for platelet function disorders and from 42 normal subjects in the hemophilia clinics of three centers with specialized laboratory facilities on three different analyzers of the Sysmex CS-2x00 series using seven agonists over a wide range of agonist concentrations (26 tests per sample in total) to match the recommendations of different national and international guidelines. [3] [4] [5] The aims of the preliminary study reported here were to:
establish which concentrations of agonists should be recommended for use on these analyzers; to establish reference ranges for maximum aggregation (MA), final aggregation (FA), lag time, slope, and disaggregation; and to determine appropriate acquisition times. A subsequent study comparing results for patients with previously confirmed platelet disorders between the Sysmex CS-2x00 series analyzers and two different dedicated platelet aggregometers will be reported separately.
| MATERIAL S AND ME THODS

| Sample preparation
As part of routine practice for patients being tested for platelet disorders, 20 mL whole blood was collected into 0.105-0.109 M sodium citrate in a ratio of one part anticoagulant to 9 parts whole blood: two laboratories used samples collected using Vacutainers (Beckton-Dickinson, Oxford, UK); one laboratory used samples collected using Vacuette (Greiner Bio-One Ltd, Stonehouse, UK).
Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were prepared in line with local laboratory standard operating procedures, which adhere to the guidelines set by the BSH. 4 Platelet count on PRP was measured on local laboratory full blood count analyzers to ensure that there were enough platelets to perform aggregometry 
| Analyzers
All samples were tested by LTA on a Sysmex CS-2x00 series analyzer (Sysmex UK, Milton Keynes, UK) using standard protocols. Three different analyzers were used: a Sysmex CS-2100i; a Sysmex CS-2400;
and a Sysmex CS-2500. The Sysmex CS-2400 (without cap-piercing capability) and Sysmex CS-2500 (with cap-piercing capability) analyzers are updated versions of the Sysmex CS-2100i analyzer with an updated exterior appearance and enhanced PC software. The
Essentials
• Platelet function assays are poorly standardized between laboratories.
• Three current guidelines give different advice on agonist concentrations and acquisition times.
• Sysmex CS-2x00 analyzer enabled standardization of platelet function assays in a multicenter study.
• Agonist concentrations, acquisition times, and reference ranges were optimized for automated technique.
analytical modules and analytical software are identical on the three analyzers.
Samples were concurrently assayed by LTA on existing dedicated platelet aggregometers in the participating laboratories.
Two laboratories used a Biodata PAP-8E (Alpha Laboratories, Hampshire, UK) and one used a Helena AggRam (Helena Biosciences Europe). Data obtained from these analyses will be used for future comparative studies between the different LTA techniques.
Tubes of PPP and PRP were placed on the Sysmex CS-2x00 analyzer sampler unit, and PRP was mixed by multiple gentle inversions immediately before analysis. The analyzer aspirated PPP or PRP directly from the sample rack in micro mode, rather than taking a daughter specimen sufficient for all requested tests.
On the Sysmex CS-2x00 series analyzers, 100% aggregation was defined by observing the absorbance of 140 μL PPP to which 20 μL normal saline had been added. For analysis of PRP, the analyzer pipetted 140 μL PRP into a plastic stir-bar cuvette before addition of 20 μL of agonist (7:1 PRP to agonist), at which point 0% aggregation is defined by the instrument. Absorbance was monitored for 600 seconds whilst the contents of the cuvette were stirred at a constant 800 rpm. All assays were completed within 4 hours of sample collection.
At the end of the measuring period traces were saved as PDF files, and raw data were entered into a Microsoft Excel spreadsheet (Microsoft, Redmond, WA, USA).
Data were analyzed using GraphPad Prism 7.0 for Windows (GraphPad Software, La Jolla, CA, USA).
| Reagents
All laboratories used the same reagents on the Sysmex CS-2x00 The ISTH 5 guideline does not recommend testing ADP at concentrations lower than 2 μM or epinephrine below 5 μM, but CLSI 3 and BSH 4 guidelines recommend testing both at lower concentrations, although neither suggests when this could be clinically useful. A single lower concentration of 1 μM ADP was included in the study, which was a one-half dilution of the 2 μM agonist, selected for ease of preparation. A concentration of epinephrine below 5 μM was not included in the study.
TA B L E 2 Reference ranges
To check for spontaneous aggregation, normal saline was used in place of an agonist with all assays.
The agonists selected and their final concentrations when mixed with PRP are summarized in Table 1 . One-way ANOVA analysis showed that there were no statistically significant differences between results for controls obtained at each site, despite the different blood collection tubes used and the different reagent handling. Therefore data was combined and reference ranges were established by finding the 2.5th to 97.5th percentile for each parameter from samples collected from 42 volunteers with no history of bleeding and no recent NSAID use. The results are summarized in Table 2 .
| RESULTS
| Differences between agonists
Comparisons were made between the MA for each agonist concentration and also between FA for each agonist concentration for all samples tested. Analysis for normality by Shapiro-Wilk test showed that only the MA for ADP at 20 and 2 μM, collagen at 1 μg/mL, TRAP at 20 and 10 μM, and ristocetin at 1.25 g/L were normally distributed. Only the FA for ADP at 20 μM, collagen at 5, 2.5, and 1 μg/mL, TRAP at 20 μM and ristocetin at 1.25 g/L were normally distributed.
Therefore all comparisons were made by the non-parametric Tukey test, summarized in Table 3 .
The MA for each agonist and concentration in controls are shown in Figure 1 .
| Acquisition time
ISTH guidelines state that aggregation should be monitored for a minimum of 3 minutes after adding an agonist, or 5 minutes if MA for an agonist in most control samples is not achieved within 3 minutes, or 10 minutes if MA for an agonist in most controls samples is not achieved within 5 minutes. 5 Time to MA in controls where the percentage MA exceeded 20%
was assessed for each agonist, and is shown in Figure 2 .
The 97.5th percentile was used to determine the time by which most control samples had achieved MA. This exceeded 180 seconds for all agonists tested, and was below 300 seconds only for TRAP at 20, 10, and 5 μM, U46619 at 1 μM, ADP at 20, and 10 μM, collagen at 1.25 and 1.00 μg/mL, and ristocetin at 1.50 g/L. For all other agonists and concentrations tested, the 97.5th percentile exceeded 300 seconds.
| Patients with platelet function disorders
In patients being investigated for platelet disorders, the platelet 
| DISCUSSION
The preliminary results from normal subjects in this multisite study show that a standardized protocol for platelet aggregation studies can be applied using these analyzers. We have generated reference ranges for MA, FA, lag time, slope, and disaggregation, against which local laboratories can verify this method.
These preliminary results show that there was no significant difference in the results for MA, FA, lag time, or slope obtained using ADP at 20 or 10 μM in the normal donors, and therefore it is not necessary to test ADP at concentrations above 10 μM for the investigation of heritable platelet disorders, since using a higher concentration risks over-activating abnormal platelets and generating potentially misleading normal responses. This is in contrast to the recommendations of BSH. 4 There was no significant difference for showed aggregation at 1 μM concentration as recommended by the various guidelines. [3] [4] [5] Maximum aggregation was reached within 300 seconds for U46619 but more than 300 seconds for all concentrations of arachidonic acid tested. We recommend that laboratories using the CS-2x00 analyzers use a concentration of 1 mM arachidonic acid with an acquisition time of 600 seconds in line with BSH recommendations, 4 but a shorter acquisition time of 300 seconds could be used for 1 μM U46619 in line with ISTH recommendations.
5
There was no significant difference in the results obtained for MA, FA, lag time, or slope between any of the concentrations of collagen that were analyzed, except for a statistical difference in lag time between 2.5 and 1.25 μg/mL (P = 0.039). Maximum aggregation was reached within 300 seconds using 1 and 1.25 μg/mL collagen but slightly more than 300 seconds for 2.5 and 5 μg/mL collagen. It does not appear to be necessary to test collagen above a concentration of 2.5 μg/mL since using a higher concentration risks overactivating abnormal platelets and generating potentially misleading normal responses. We recommend that laboratories using the CS2x00 analyzers use concentrations of collagen of 1.25 and 2.5 μg/mL with an acquisition time of 600 seconds.
There was no significant difference in the results for MA, FA, lag time, or slope obtained using ristocetin at suggests that there may be little diagnostic value in repeating testing with higher doses of epinephrine, especially if this is the only abnormality noted. Low doses of epinephrine can be used to detect the minimum dose that induces secondary aggregation but although the CLSI 3 or BSH 4 guidelines suggest testing using lower doses if the response to 5 μM epinephrine is normal, neither state how this is useful in the diagnosis of a bleeding disorder: the ISTH guidelines 5 state only that higher doses need to be tested if the response to 5 μM epinephrine is abnormal. Maximum aggregation was reached within 600 seconds for both doses of epinephrine used in this study. We recommend that laboratories using the CS-2x00 analyzers use a concentration of epinephrine of 5 μM with an acquisition time of 600 seconds.
There was no significant difference in the results for MA, FA, lag time, or slope obtained using TRAP at 20, 10 or 5 μM: there was also no difference for MA, FA, lag time, or slope using TRAP at 1 μM or using saline as agonist (although two controls did respond to this dose of TRAP). BSH 4 and ISTH 5 guidelines recommend using concentrations of TRAP of at least 10 μM, but we saw good response at 5 μM in most cases. The dose of TRAP that is needed to discriminate between normal and abnormal platelet aggregation is likely to be between 5 and 1 μM. Maximum aggregation was reached within 300 seconds for all doses of TRAP except 1 μM. We recommend that laboratories using the CS-2x00 analyzers use a concentration of TRAP of 5 μM with an acquisition time of 300 seconds. A minimum dose of TRAP required for platelet aggregation is yet to be elucidated.
As a result of these experiments, our recommendations for agonist concentrations and acquisition times mapped to the guidelines are presented in Table 4 .
Using these agonist concentrations and acquisition times on the CS-2x00 analyzers, we obtained the expected results for a patient with a genetically confirmed diagnosis of Glanzmann's Thromboasthenia, and for a patient with a genetically confirmed COX-1 deficiency. Two patients who had been previously characterized with aspirin-like defects and one who had been previously diagnosed with a storage pool disease also gave the expected results, and all patients with normal platelet aggregation by dedicatedanalyzer LTA had normal platelet aggregation with the CS-2x00
analyzers (data not shown). The findings from this preliminary optimization study will form the basis of the next phase of the study in which a wider group of patients with characterized disorders will be tested, including some with Bernard Soulier Syndrome and von Willebrand disease.
It should be noted that this study used only one manufacturer as a source for each agonist, and that reagents from other manufacturers may give different results. Only Sysmex CS-2x00 analyzers were included in the study, but as the Sysmex CS-5100 analyzer uses the same analytical software these findings may be applicable to that analyzer. The Sysmex CS-5100 has more detectors available for platelet function and therefore potentially higher throughput. As analyses are performed in micro mode, there is a risk that platelets will settle out of suspension while waiting to be analyzed by the analyzer: we have not tested this and it should be noted as a limitation of our study.
In conclusion, this method allows for greater standardization of the analysis of platelet function, although pre-analytical preparation of platelet poor plasma and platelet rich plasma is still a timeconsuming process that may also be a source of inter-laboratory variation. The Sysmex CS-2x00 analyzers allow for platelet ag- 
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